Home › Funds › Siren, L.L.C. › DMRA
Siren, L.L.C. position in DMRA
Damora Therapeutics Inc · Health Care
Siren, L.L.C. reported holding 900,000 shares of DMRA (Damora Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$19.2M, representing 0.45% of its reported portfolio and ranking #50 among its reported holdings. Siren, L.L.C. has disclosed DMRA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s DMRA position evolved
Siren, L.L.C. first disclosed a stake in DMRA in Q1 2026 at 900,000 shares (US$23.3M). The position peaked in Q2 2026 at 900,000 shares, worth US$23.4M. Across 3 filings, Siren, L.L.C. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 900,000 shares valued at US$19.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 900.00K | $23.31M | New |
| Q2 2026 | 900.00K | $23.41M | Hold |
| Q3 2026 | 900.00K | $19.15M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMRA and 13F data
DMRA (Damora Therapeutics Inc) is a Health Care company. 106 other funds we track also report a position in DMRA — the largest reported positions include Fairmount Funds Management LLC (US$226.6M), Avoro Capital Advisors LLC (US$98.4M), Venrock Adviser, LLC (US$93.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMRA
- Fairmount Funds Management LLC 8.71M sh · $226.63M · Q2 2026
- Avoro Capital Advisors LLC 3.78M sh · $98.40M · Q2 2026
- Venrock Adviser, LLC 3.60M sh · $93.73M · Q2 2026
- FCPM III SERVICES B.V. 2.44M sh · $63.49M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $62.42M · Q2 2026
- Remedium Capital Partners, LLC 2.05M sh · $53.20M · Q2 2026
- Commodore Capital LP 1.94M sh · $50.43M · Q2 2026
- BRAIDWELL LP 1.62M sh · $42.15M · Q2 2026
- Bellevue Group AG 1.62M sh · $42.11M · Q2 2026
- a16z Capital Management, L.L.C. 1.24M sh · $32.15M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $31.81M · Q2 2026
- Cormorant Asset Management, LP 1.00M sh · $26.01M · Q2 2026
More on Siren, L.L.C.
FAQ
How long has Siren, L.L.C. held DMRA?
Siren, L.L.C. has disclosed DMRA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Siren, L.L.C.'s current position in DMRA?
As of Q3 2026, Siren, L.L.C. holds 900.00K shares of DMRA (Damora Therapeutics Inc), valued at $19.15M, representing 0.45% of its reported portfolio and ranking #50.
Has Siren, L.L.C. been buying or selling DMRA?
In the latest 13F filing (Q3 2026), Siren, L.L.C. held unchanged its position in DMRA. The position peaked in Q2 2026 at 900.00K shares.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.